Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 15/20 | 0.84 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6189010 | 1.00 | MCHR1 (0.84) | MCHR1KCNH2MAPTUSP2LMNA | |
| SCHEMBL6191911 | 0.93 | MCHR1 (0.86) | MCHR1KCNH2MAPTUSP2LMNA | |
| SCHEMBL6191913 | 0.93 | MCHR1 (0.86) | MCHR1KCNH2MAPTUSP2LMNA | |
| SCHEMBL6189741 | 0.93 | MCHR1 (0.80) | MCHR1KCNH2MAPTUSP2LMNA | |
| SCHEMBL6189738 | 0.93 | MCHR1 (0.80) | MCHR1KCNH2MAPTUSP2LMNA | |
| SCHEMBL6189421 | 0.91 | MCHR1 (1.00) | MCHR1KCNH2MAPTUSP2LMNA | |
| SCHEMBL6189419 | 0.91 | MCHR1 (1.00) | MCHR1KCNH2MAPTUSP2LMNA | |
| SCHEMBL6190416 | 0.90 | MCHR1 (0.73) | MCHR1KCNH2MAPTUSP2LMNA | |
| SCHEMBL6190413 | 0.90 | MCHR1 (0.73) | MCHR1KCNH2MAPTUSP2LMNA | |
| SCHEMBL6189465 | 0.89 | MCHR1 (0.79) | MCHR1KCNH2MAPTUSP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921821-B2 | Antagonists of melanin concentrating hormone receptor | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | claimed |
| EP-1534703-A2 | ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR | ABBOTT LABORATORIES (US) | 2005-06-01 | — | — | EP | claimed |
| US-20040106645-A1 | Antagonists of melanin concentrating hormone receptor | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | claimed |
| WO-2003106452-A2 | ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-12-24 | — | — | WO | claimed |
| US-6921821-B2 | Antagonists of melanin concentrating hormone receptor | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1534703-A2 | ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR | ABBOTT LABORATORIES (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040106645-A1 | Antagonists of melanin concentrating hormone receptor | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | disclosed |
| WO-2003106452-A2 | ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106645-A1 | Antagonists of melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | MCHR1 1/4885KCNH2 2839/4885MAPT 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.